(I)

U.S. Application No.: 10/549,250 Inventors: Carlos Garcia-Echeverria et al. International Filing Date: 12 March 2004

Response to Final Office Action dated May 20, 2010

Page 2

CLAIMS

1. (Currently Amended) A compound of formula I

wherein

each of R⁰, R¹, and R², independently is hydrogen, C₁-C₈alkyl, C₂-C₈alkenyl, C₂-C₈alkinyl, C₃-C₈cycloalkyl, C₃-C₈cycloalkylC₁-C₈alkyl, C₅-C₁₀arylC₁-C₈alkyl, hydroxyC₁-C₈alkyl, C₁-C₈alkyl, aminoC₁-C₈alkyl, haloC₁-C₈alkyl, unsubstituted or substituted C₅-C₁₀aryl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1, 2 or 3 hetero atoms selected from N, O and S, hydroxy, C₁-C₈alkoxy, hydroxyC₁-C₈alkoxy, C₁-C₈alkoxy, haloC₁-C₈alkoxy, unsubstituted or substituted or substituted or substituted or substituted heterocyclyloxy, [or] unsubstituted or substituted heterocyclylC₁-C₈alkoxy, unsubstituted amino, C₁-C₈alkylthio, C₁-C₈alkylsulfinyl, C₁-C₈alkylsulfonyl, C₅-C₁₀arylsulfonyl, halogen, carboxy, C₁-C₈alkoxycarbonyl, unsubstituted or substituted carbamoyl, unsubstituted sulfamoyl, cyano or nitro;

 R^3 is C_1 - C_8 alkylsulfinyl, C_1 - C_8 alkylsulfonyl, C_5 - C_{10} arylsulfonyl, \underline{or} unsubstituted or substituted carbamoyl or unsubstituted or substituted sulfamoyl;

Or the pair of adjacent substituents R^2 and R^3 forms $-CH_2$ -NH-CO- or $-CH_2$ -NH-SO₂- or such pairs wherein NH is substituted by C_1 - C_8 -alkyl;

 R^4 is hydrogen or C_1 - C_8 alkyl;

R⁵ is halogen;

R⁶ is hydrogen;

each of R⁵ and R⁶ independently is hydrogen, C₁-C₈alkyl, C₁-C₈alkoxyC₁-C₈alkyl, haloC₁-C₈alkyl, C₁-C₈alkoxy, halogen, carboxy, C₁-C₈alkoxycarbonyl, unsubstitued or substituted carbamoyl, cyano, or nitro; and

each of R^7 , R^8 , R^9 , and R^{10} independently is C_1 - C_8 alkyl, C_2 - C_8 alkenyl, C_2 - C_8 alkinyl, C_3 - C_8 cycloalkyl, C_3 - C_8 cycloalkyl, C_5 - C_{10} aryl C_1 - C_8 alkyl, hydroxy C_1 - C_8 alkyl, $C_$

<u>PATENT</u> PAT032910A-US-PCT

U.S. Application No.: 10/549,250 Inventors: Carlos Garcia-Echeverria et al. International Filing Date: 12 March 2004

Response to Final Office Action dated May 20, 2010

Page 3

 C_8 alkoxy C_1 - C_8 alkyl, amino C_1 - C_8 alkyl, halo C_1 - C_8 alkyl, unsubstituted or substituted C_5 - C_{10} aryl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1, 2 or 3 hetero atoms selected from N, O and S, hydroxy, C_1 - C_8 alkoxy, hydroxy C_1 - C_8 alkoxy, halo C_1 - C_8 alkoxy, unsubstituted or substituted C_5 - C_{10} aryl C_1 - C_8 alkoxy, unsubstituted or substituted or substituted heterocyclyloxy, [or] unsubstituted or substituted heterocyclyl C_1 - C_8 alkoxy, unsubstituted or substituted amino, C_1 - C_8 alkylthio, C_1 - C_8 alkylsulfinyl, C_1 - C_8 alkylsulfonyl, C_5 - C_{10} arylsulfonyl, halogen, carboxy, C_1 - C_8 alkoxycarbonyl, unsubstituted or substituted carbamoyl, unsubstituted or substituted sulfamoyl, cyano or nitro; wherein R^7 , R^8 and R^9 independently of each other can also be hydrogen;

or R^7 and R^8 , R^8 and R^9 , and/or R^9 and R^{10} form together with the carbon atoms to which they are attached, a 5 or 6 membered carbocyclic or heterocyclic ring comprising 0, 1, 2 or 3 heteroatoms selected from N, O and S that is unsubstituted or substituted by C_1 - C_8 -alkyl, C_1 - C_8 -alkoxy, halo- C_1 - C_8 -alkyl, hydroxyl, amino, substituted amino, halogen, carboxy, C_1 - C_8 alkoxycarbonyl, carbamoyl, cyano, or oxo;

A is C;

and salts thereof.

- 2. (Currently Amended) A compound of formula I according to claim 1, wherein each of R⁰ or R² independently is hydrogen, C₁-C₈alkyl, hydroxyC₁-C₈alkyl, haloC₁-C₈alkyl, unsubstituted or substituted C₅-C₁₀aryl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 hetero atoms selected from N, O and S, C₁-C₈alkoxy, haloC₁-C₈alkoxy, C₅-C₁₀aryloxy, unsubstituted or substituted heterocyclyloxy, unsubstituted or substituted or substituted amino, C₁-C₈alkylsulfonyl, halogen, unsubstituted or substituted carbamoyl, or unsubstituted or substituted sulfamoyl;
- R¹ is hydrogen, C₁-C₈alkyl, hydroxyC₁-C₈alkyl, haloC₁-C₈alkyl, unsubstituted or substituted C₅-C₁₀aryl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 hetero atoms selected from N, O and S, C₁-C₈alkoxy, haloC₁-C₈alkoxy, C₅-C₁₀aryloxy, unsubstituted or substituted heterocyclyloxy, unsubstituted or substituted heterocyclyloxy, unsubstituted or substituted sulfamoyl;

Response to Final Office Action dated May 20, 2010

Page 4

- R³ is C₁-C₈alkylsulfinyl, C₁-C₈alkylsulfonyl, C₅-C₁₀arylsulfonyl, or unsubstituted or substituted carbamoyl or unsubstituted or substituted sulfamoyl;
- or the pair of adjacent substituents R² and R³ forms –CH₂-NH-CO- or CH₂-NH-SO₂- or such pairs wherein NH is substituted by C₁-C₈-alkyl;

 R^4 is hydrogen or C_1 - C_8 alkyl;

R⁵ is chloro or bromo;

R⁵ is hydrogen; C₁ C₈alkyl, halogen, haloC₁ C₈alkyl, cyano or nitro;

R⁶ is hydrogen;

- each of R⁷ and R⁹ independently is hydrogen, C₁-C₈alkyl, hydroxyC₁-C₈alkyl, haloC₁-C₈alkyl, unsubstituted or substituted C₅-C₁₀aryl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 hetero atoms selected from N, O and S, C₁-C₈alkoxy, haloC₁-C₈alkoxy, C₅-C₁₀aryloxy, unsubstituted or substituted heterocyclyloxy, unsubstituted or substituted amino, C₁-C₈alkylsulfonyl, halogen, unsubstituted or substituted carbamoyl, or unsubstituted or substituted sulfamoyl;
- R⁸ is hydrogen, C₁-C₈alkyl, hydroxyC₁-C₈alkyl, haloC₁-C₈alkyl, C₅-C₁₀aryl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 hetero atoms selected from N, O and S, C₁-C₈alkoxy, haloC₁-C₈alkoxy, C₅-C₁₀aryloxy, unsubstituted or substituted heterocyclyloxy, unsubstituted or substituted heterocyclylC₁-C₈alkoxy, unsubstituted or substituted amino, C₁-C₈alkylsulfonyl, halogen, unsubstituted or substituted carbamoyl, unsubstituted or substituted sulfamoyl, cyano, or nitro; and
- R¹⁰ is C₁-C₈alkyl, hydroxyC₁-C₈alkyl, haloC₁-C₈alkyl, C₁-C₈alkoxy, unsubstituted or substituted heterocyclylC₁-C₈alkoxy, unsubstituted or substituted amino, halogen, carboxy, carbamoyl, or unsubstituted or substituted sulfamoyl; or
- each pair of adjacent substituents R^7 and R^8 , or R^8 and R^9 or R^9 and R^{10} , is –NH-CH=CH-, -CH=CH-NH-, -NH-N=CH-, -CH=N-NH-, -CH₂-CH₂-CH₂-, -CH₂-CH₂-CH₂-CH₂-CH₂-CH₂-, -CH₂-CH₂-O-, -CH=CH-O-, -O-CH₂-O-, or -O-CF₂-O-; and A is C.
- **3.** (Currently Amended) A compound of formula I according to claim 1, wherein each of R⁰ or R² independently is hydrogen, C₁-C₈alkyl, haloC₁-C₈alkyl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 hetero atoms selected from

Response to Final Office Action dated May 20, 2010

Page 5

- N, O and S, C₁-C₈alkoxy, unsubstituted or substituted heterocyclyloxy, unsubstituted or substituted heterocyclylC₁-C₈alkoxy, unsubstituted or substituted amino, or halogen;
- R¹ is hydrogen, C₁-C₈alkyl, haloC₁-C₈alkyl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 hetero atoms selected from N, O and S, C₁-C₈alkoxy, unsubstituted or substituted heterocyclyloxy, unsubstituted or substituted heterocyclylC₁-C₈alkoxy, unsubstituted or substituted amino, or halogen;
- R³ is C₁-C₈alkylsulfinyl, C₁-C₈alkylsulfonyl, C₅-C₁₀arylsulfonyl, <u>or</u> unsubstituted or substituted carbamoyl or unsubstituted or substituted sulfamoyl;
- or the pair of adjacent substituents R^2 and R^3 forms $-CH_2$ -NH-CO- or CH_2 -NH-SO₂- or such pairs wherein NH is substituted by C_1 - C_8 -alkyl;

R⁴ is hydrogen;

R⁵ is chloro or bromo;

R⁵ is hydrogen, halogen, haloC₁-C₈alkyl, or nitro;

R⁶ is hydrogen;

- each of R⁷ and R⁹ independently is hydrogen, C₁-C₈alkyl, haloC₁-C₈alkyl, unsubstituted or substituted C₅-C₁₀aryl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 hetero atoms selected from N, O and S, C₁-C₈alkoxy, unsubstituted or substituted heterocyclyloxy, unsubstituted or substituted heterocyclylC₁-C₈alkoxy, unsubstituted or substituted amino, halogen, unsubstituted or substituted carbamoyl, or unsubstituted or substituted sulfamoyl;
- R⁸ is hydrogen, C₁-C₈alkyl, haloC₁-C₈alkyl, C₅-C₁₀aryl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 hetero atoms selected from N, O and S, C₁-C₈alkoxy, haloC₁-C₈alkoxy, C₅-C₁₀aryloxy, unsubstituted or substituted heterocyclyloxy, unsubstituted or substituted heterocyclylC₁-C₈alkoxy, unsubstituted or substituted amino, halogen, unsubstituted or substituted sulfamoyl, or nitro; and
- R^{10} is C_1 - C_8 alkyl, halo C_1 - C_8 alkyl, C_1 - C_8 alkoxy, unsubstituted or substituted heterocyclyl C_1 - C_8 alkoxy, unsubstituted or substituted amino, or halogen; or
- each pair of adjacent substituents R^7 and R^8 , or R^8 and R^9 or R^9 and R^{10} , is –NH-CH=CH-, -CH=CH-NH-, -NH-N=CH-, -CH=N-NH-, -CH₂-CH₂-CH₂-, -CH₂-CH₂-CH₂-CH₂-, -O-CH₂-O-, or -O-CF₂-O-; and

A is C.

Response to Final Office Action dated May 20, 2010

Page 6

10. (Previously Presented) A process for the production of a compound of formula I according to claim 1, comprising reacting a compound of formula II

wherein R⁰, R¹, R², R³, R⁴, R⁵, and R⁶ are as defined in claim 1, and Y is a leaving group, with a compound of formula III

$$H_2N$$
 R^7
 R^8
 R^9
 R^{10}
(III)

wherein A, R⁷, R⁸, R⁹ and R¹⁰ are as defined in claim 1;

and, if desired, converting a compound of formula I, wherein the substituents have the meaning as defined in claim 1, into another compound of formula I as defined in claim 1; and recovering the resulting compound of formula I in free from or as a salt, and, when required, converting the compound of formula I obtained in free form into the desired salt, or an obtained salt into the free form.

- 11. (Previously Presented) A pharmaceutical composition comprising a compound according to claim 1, as active ingredient together with one or more pharmaceutically acceptable diluents or carriers.
 - **12.** (Canceled).
- 13. (Previously Presented) A combination comprising a therapeutically effective amount of a compound according to claim 1 and one or more known drug substances, said further drug substance being useful in the treatment of neoplastic diseases or immune system disorders.

Response to Final Office Action dated May 20, 2010

Page 7

14. (Previously Presented) A method for the treatment of breast tumors in a subject in need thereof which comprises administering an effective amount of a compound according to claim 1 or a pharmaceutical composition comprising same.

15-24. (Canceled).

25. (New) A compound of the formula I shown in claim 1, wherein each of R^0 , R^1 or R^2 is hydrogen.

- **26.** (New) A compound of the formula I shown in claim 1, wherein R⁸ is hydrogen, methyl, piperidino, piperazino, N-methylpiperazino, morpholino, methoxy, ethoxy, trifluoromethoxy, phenoxy, 1-methyl-4-piperidyloxy, 3-morpholinopropoxy, 2-morpholinoethoxy, 3-(N-methylpiperazino)-propoxy, methylamino, fluoro, chloro, sulfamoyl or nitro.
- **27.** (New) A compound of the formula I as shown in claim 1, wherein R^{10} is C_1 - C_8 alkyl, halo C_1 - C_8 alkyl, C_1 - C_8 alkoxy, unsubstituted or substituted heterocycylyl C_1 - C_8 alkoxy, unsubstituted or substituted amino, or halogen.
- **28.** (New) A compound of the formula I shown in claim 1, selected from the group of compounds with the following names or formulae: 2-[5-chloro-2-(2-methoxy-4-morpholin-4-yl-phenylamino)-pyrimidin-4-ylamino]-N-methylbenzamide;

a compound of the formula given in the following table:

Response to Final Office Action dated May 20, 2010

	l p
Compound No.	Rx
7-1	
7-2	NH ₂
7-3	No N
7-4	
7-5	

7-6	ON ON
7-7	Z Z Z Z
7-8	OH OH
7-9	
7-10	

7-11	
7-12	
7-13	N ^T H
7-14	
7-17	NH ₂

Response to Final Office Action dated May 20, 2010

7-18	NH ₂
7-19	
7-20	
7-21	
7-22	

Response to Final Office Action dated May 20, 2010

	,
7-23	¥ − − − − − − − − − − − − − − − − − − −
7-24	ON NO N
7-25	
7-26	
7-27	
7-28	

Response to Final Office Action dated May 20, 2010

Page 13

a compound of the formula given in the following table:

Compound	Rx
8-1	ON ON ON
8-2	
8-3	F
8-4	F ;

Response to Final Office Action dated May 20, 2010


Page 14

a compound of the formula given in the following table:

Compound	Rx
9-1	
9-2	N N N N N N N N N N N N N N N N N N N
9-3	No N
9-4	

Response to Final Office Action dated May 20, 2010

Page 15



a compound of the formula given in the following table:

Compound Rx

10-1

Response to Final Office Action dated May 20, 2010

Page 16

a compound of the formula given in the following table:

Compound	Rx
11-1	
11-2	

Response to Final Office Action dated May 20, 2010

Page 17

7-[5-chloro-2-(2-methoxy-4-morpholin-4-yl-phenylamino)-pyrimidin-4-ylamino]-2-methyl-2,3-dihydro-isoindol-1-one;

a compound of the formula given in the following table:

Compound	Rx
12-2	
12-3	OH OH

Response to Final Office Action dated May 20, 2010

Page 18

12-4	
12-5	;

a compound of the formula

, wherein Rx has one of the

meanings given in the following table:

Compound.	Rx
13-1	<u> </u>
	N
	l I

PAT032910A-US-PCT

Response to Final Office Action dated May 20, 2010

Page 19

a compound of the formula

, wherein Ry has one of the meanings given in

the following table:

Compound	Ry
14-1	
14-2	_\n__\
14-3	
	NH F
14-5	O NH
14-6	

U.S. Application No.: 10/549,250 PAT032910A-US-PCT Inventors: Carlos Garcia-Echeverria et al.

International Filing Date: 12 March 2004

Page 20

Response to Final Office Action dated May 20, 2010

a compound of the formula given in the following table:

Compound	Rx
15-1	
15-2	
15-3	, ;

Response to Final Office Action dated May 20, 2010

Page 21

PATENT PAT032910A-US-PCT

a compound of the formula

, wherein Ry has one of the

meanings given in the following table:

Compound	Ry
16-1	
16-2	N N
16-3	0
16-4	-x -x -x -y -y -y -y -y -y -y -y -y -y -y -y -y

a compound of the formula given in the following table:

Response to Final Office Action dated May 20, 2010

Page 22

Compound	Rx
18-1	

a compound of the formula

, wherein Rx has one of the

meanings given in the following table:

Compound	Rx
26-1	N O
26-2	N N Ac
26-3	

	·
26-4	→ No. 10 10 10 10 10 10 10 10 10 10 10 10 10
26-5	NH ₂
26-6	
26-7	N Ac
26-8	

26-9	
26-10	Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z
26-11	N Ac
26-12	NH ₂

26-13	NH ₂
26-14	O NH
26-15	Ac N
26-17	
26-18	

Response to Final Office Action dated May 20, 2010

26-19	
26-20	
26-21	
26-22	No.
26-23	N N N N N N N N N N N N N N N N N N N

26-24	
26-25	NH NH
26-26	
26-27	OH OH
26-28	OH OH

Response to Final Office Action dated May 20, 2010

26-29	
26-30	F
26-31	N N N N N N N N N N N N N N N N N N N
26-32	
26-33	
26-34	
26-35	HO

Response to Final Office Action dated May 20, 2010

Page 29

26-36	
26-37	HN
26-38	
26-39	NH ₂ ;

a compound of the formula given in the following table:

Compound	Rx
27-1	
	, i

27-2	
27-3	
27-4	
27-5	
27-6	O NH ₂

Response to Final Office Action dated May 20, 2010

Page 31

a compound of the formula given in the following table:

Compound	Rx
28-1	NH ₂
28-2	OH OH

Response to Final Office Action dated May 20, 2010

28-3	
28-4	
28-5	~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
28-6	
28-7	- N

Response to Final Office Action dated May 20, 2010

28-8	
28-9	
28-10	
28-11	N Ac

Response to Final Office Action dated May 20, 2010

28-12	N N N N N N N N N N N N N N N N N N N
28-13	
28-14	
28-15	H ₂ N O

Response to Final Office Action dated May 20, 2010

28-16	J O J J
28-17	
28-18	
28-19	
28-20	Z Z Z

Response to Final Office Action dated May 20, 2010

28-21	Z Z
28-22	
28-23	
28-24	

Response to Final Office Action dated May 20, 2010

28-25	
28-27	NH _{NH₂}
28-28	NH ₂
28-29	
28-30	

U.S. Application No.: 10/549,250

Inventors: Carlos Garcia-Echeverria et al.

International Filing Date: 12 March 2004

PATENT
PAT032910A-US-PCT

Response to Final Office Action dated May 20, 2010

Page 38

a compound of the formula

, wherein Rx has one of the

Compound	Rx
29-1	o z
29-2	
29-3	, ;

Response to Final Office Action dated May 20, 2010

Page 39

a compound of the formula

, wherein Rx has one of the

Compound	Rx
30-1	
30-2	
30-3	O NH ₂
30-4	

Response to Final Office Action dated May 20, 2010

Page 40

a compound of the formula

, wherein Rx has one of the

Compound	Rx
31-1	
31-2	, ;

PAT032910A-US-PCT

Response to Final Office Action dated May 20, 2010 Page 41

a compound of the formula

, wherein Rx has one of the

meanings given in the following table:

Compound	Rx
32-1	\$-2 0 0
32-2	; ;

a compound of the formula

, wherein Rx has one of the

Response to Final Office Action dated May 20, 2010

Page 42

Compound	Rx
33-1	Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z
33-2	,

a compound of the formula

, wherein Ry has one of the meanings given in

the following table:

Compound	Ry
34-1	
34-2	o j
34-3	

Response to Final Office Action dated May 20, 2010

Page 43

34-4	
34-5	
34-6	;

a compound of the formula:

a compound of the formula given in the following table:

, wherein Rx has one of the meanings

Response to Final Office Action dated May 20, 2010

Page 44

Compound	Rx
35-1	; and
35-2	;

or a pharmaceutically acceptable salt thereof.

29. (New) A compound of formula I according to claim 1, wherein

R⁰, R¹ or R² is hydrogen;

R³ is C₁-C₈alkylsulfonyl, C₅-C₁₀arylsulfonyl or unsubstituted or substituted carbamoyl;

R⁴ is hydrogen;

R⁵ is chloro or bromo;

R⁶ is hydrogen;

each of R⁷ and R⁹ independently is hydrogen, C₁-C₈alkyl, haloC₁-C₈alkyl, unsubstituted or substituted C₅-C₁₀aryl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 hetero atoms selected from N, O and S, C₁-C₈alkoxy, unsubstituted or substituted heterocyclyloxy, unsubstituted or substituted heterocyclylC₁-C₈alkoxy, unsubstituted or substituted or substituted carbamoyl, or unsubstituted or substituted sulfamoyl;

R⁸ is hydrogen, C₁-C₈alkyl, haloC₁-C₈alkyl, C₅-C₁₀aryl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 hetero atoms selected from N, O and S, C₁-C₈alkoxy, haloC₁-C₈alkoxy, C₅-C₁₀arylC₁-C₈alkoxy, unsubstituted or substituted heterocyclyloxy, unsubstituted or substituted heterocyclylC₁-C₈alkoxy, unsubstituted or substituted amino, halogen, unsubstituted or substituted sulfamoyl, or nitro; and

 R^{10} is C_1 - C_8 alkyl, halo C_1 - C_8 alkyl, C_1 - C_8 alkoxy, unsubstituted or substituted heterocyclyl C_1 - C_8 alkoxy, unsubstituted or substituted amino, or halogen; and

A is C.

Response to Final Office Action dated May 20, 2010

Page 45

30. (New) A compound of formula I according to claim 29, wherein R⁸ is hydrogen, methyl, piperidino, piperazino, N-methylpiperazino, morpholino, methoxy, ethoxy, trifluoromethoxy, phenoxy, 1-methyl-4-piperidyloxy, 3-morpholinopropoxy, 2-morpholinoethoxy, 3-(N-methylpiperazino)-propoxy, methylamino, fluoro, chloro, sulfamoyl or nitro.

- **31.** (New) A compound of formula I according to claim 29, wherein said compound is 2-[5-chloro-2-(2-methoxy-4-morpholin-4-yl-phenylamino)-pyrimidin-4-ylamino]-N-methyl-benzamide, or a pharmaceutically acceptable salt thereof.
- **32.** (New) A compound of formula I according to claim 29, wherein said compound is N²-(4-[1,4']Bipiperidinyl-1'-yl-2-methoxy-phenyl)-5-chloro-N⁴-[2-(propane-1-sulfonyl)-phenyl]-pyrimidine-2,4-diamine, or a pharmaceutically acceptable salt thereof.
- **33.** (New) The method according to claim 14, wherein said compound is 2-[5-chloro-2-(2-methoxy-4-morpholin-4-yl-phenylamino)-pyrimidin-4-ylamino]-N-methylbenzamide, or a pharmaceutically acceptable salt thereof.
- **34.** (New) The method according to claim 14, wherein said compound is N^2 -(4-[1,4']Bipiperidinyl-1'-yl-2-methoxy-phenyl)-5-chloro- N^4 -[2-(propane-1-sulfonyl)-phenyl]-pyrimidine-2,4-diamine, or a pharmaceutically acceptable salt thereof.
 - **35.** (New) A compound having the formula

a compound of the formula given in the following table:

, wherein Rx has one of the meanings

Response to Final Office Action dated May 20, 2010

Page 46

Compound No.	Rx
7-15	O H O O
7-16	O H H C C C C C C C C C C C C C C C C C

a compound of the formula given in the following table:

, wherein Rx has one of the meanings

Compound	Rx
12-6	

PATENT PAT032910A-US-PCT

Response to Final Office Action dated May 20, 2010

Page 47

a compound of the formula

, wherein Ry has one of the meanings given in

the following table:

a compound of the formula

, wherein Rx has one of the

meanings given in the following table:

Compound	Rx
26-16	
	Z Z
	;

a compound of the formula given in the following table:

wherein Rx has one of the meanings

Response to Final Office Action dated May 20, 2010

Page 48

Compound	Rx
27-7	
	, ;

a compound of the formula given in the following table:

, wherein Rx has one of the meanings

a compound of the formula meanings given in the following table:

, wherein Rx has one of the

Response to Final Office Action dated May 20, 2010

Page 49

Compound	Rx
30-5	
	; , , , , , , , , , , , , , , , , , , ,

PAT032910A-US-PCT

or a pharmaceutically acceptable salt thereof.